New blood test detects aggressive prostate cancer more accurately than PSA, study finds

A new blood test, Stockholm3, is showing a significant leap forward in detecting aggressive prostate cancer, outperforming the long-standing PSA test. Recent research published in the Annals of Internal Medicine, led by scientists at Karolinska Institutet, reveals that Stockholm3 identified 90% of clinically significant prostate cancer cases, a marked improvement over the PSA test 74% detection rate. This breakthrough could dramatically change how prostate cancer is screened, potentially saving lives by catching dangerous cancers earlier. This development addresses a critical challenge with the traditional PSA test, which often leads to unnecessary biopsies due to its high false-positive rate and can sometimes miss aggressive tumors, resulting in delayed treatment. The Stockholm3 test, developed by A3P Biomedical, achieves this greater accuracy by combining PSA levels with other plasma protein biomarkers, genetic risk factors, and clinical information to give a more precise risk score. Studies show it has a significantly lower false-negative rate (10% vs. 26% for PSA) while maintaining a similar false-positive rate, promising to reduce painful and often unnecessary follow-up procedures like biopsies. Looking ahead, Stockholm3 is already commercially available as a Lab Developed Test in the USA and parts of Europe, though wider integration into national healthcare systems, like the UK's NHS, is still several years away. Experts believe these findings support a shift towards a more risk-adapted screening approach, making screening more efficient and effective. The ongoing validation across diverse ethnic groups and its potential to work alongside imaging techniques like MRI signal a future where prostate cancer detection is far more targeted and less burdensome for patients.